Viewing data from:

TRI-LO-MILI

ANDA

ETHINYL ESTRADIOL; NORGESTIMATE | A205762 | AUROBINDO PHARMA LTD

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Tri-Lo-Mili (2023)

Total Spending

$151K

Total Claims

3,982

Beneficiaries

1,171

Avg Cost/Unit

$0.68

Spending Trend

$1K(2019)→$84K(2020)→$105K(2021)→$59K(2022)→$151K(2023)

YoY Change:+1.8%

5yr CAGR:-10.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Nov 4, 2016

No patent or exclusivity listings for this strength.